You are here
Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains
CALGARY, Alberta, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today the publication of a scientific article in the prestigious Journal of Medicinal Chemistry entitled: “Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine”.
"I am very proud of the team,” stated Mr. Donald McCaffrey, President and Chief Executive Officer. “Since the spin-out from Resverlogix Corp. just five years ago, Zenith has evolved into a leader in epigenetics. Not only are we at the forefront of clinical development of BET inhibitors with our ZEN-3694 program, but we continue to advance science and contribute to the evolving field of epigenetic research. The current publication and the selection for the cover page of the Journal of Medicinal Chemistry is an excellent example of the innovative science ongoing at Zenith.”
By targeting a methionine amino acid located in the active site with a novel BET inhibitor capable of forming a chemical bond to the protein, Zenith has found a way to create a longer lasting duration of action, offering durable target modulation. Potentially, this could lead to inhibitors with a desired pharmacological effect at lower doses than is needed with current BET inhibitors.
Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.’s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (“mCRPC”).
For further information, please contact:
Investor Relations & Communications